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Objective: To compare the efficacy of Alfacalcidol (I.V) and Paricalcitol (I.V) for the treatment of secondary 
hyperparathyroidism (SHPT) in hemodialysis patients. 
Material and Methods: An open-label randomized clinical trial was carried out to compare the efficacy of 
intravenous paricalcitol and alfacalcidol. We recruited 80 patients with end-stage renal disease receiving 
maintenance hemodialysis in a tertiary care hospital dialysis unit. The participants were randomly divided into 
two groups. A wash-out period of one week was decided for each patient in whom he/she did not receive any 
medication for the treatment of hypocalcemia, hyperphosphatemia, or secondary hyperparathyroidism. 
Afterward, patients received an expanding dosage of alfacalcidol or paricalcitol for a time of about four months, 
and then after a further washout period of one week, each group received opposite treatment (paricalcitol or 
alfacalcidol) for a further four months (16 weeks). 
Results: The analyzed data for the same end-points revealed no difference between the two groups. No 
significant statistical difference in terms of calcium levels in both groups was noted. The study also found no big 
difference in the ability of both drugs to treat secondary hyperparathyroidism, while keeping serum phosphate 
and calcium levels inside the desired range. The study also found no distinction in the frequency of hypercalcemia 
and hyperphosphatemia as a side effect of Vitamin D analogue’s treatment. 
Conclusion: The study concludes that alfacalcidol and paricalcitol are equally effective in the treatment of 
secondary hyperparathyroidism in the dialysis population. Since Paricalcitol is expensive as compared to 
alfacalcidol, in an economically challenged country like Pakistan, Alfacalcidol can be a better choice when treating 
SHPT as we did not find any gross difference in the ability of two drugs to restrict SHPT. 
Keywords:  Alfacalcidol, Paricalcitol, Secondary hyperparathyroidism, Hemodialysis. 
 




Secondary hyperparathyroidism is a common 
complication of chronic kidney disease especially in 
patients on hemodialysis. The reduced ability of 
kidneys to convert vitamin D to its active form results 
in hypocalcemia. Hyperphosphatemia results due to 
the decreased ability of kidneys to remove enough 
PO4 from the body. Hypocalcemia is the main 
stimulant for the parathyroid hormone and ultimately 
patients with CKD go on to develops secondary 
hyperparathyroidism. 
Management of bone mineral disease in dialysis 
patients sometimes becomes difficult as clinicians face 
the challenge of treating secondary 
hyperparathyroidism while keeping calcium and 
phosphate within normal ranges.1 Vitamin D 
analogues are the usual treatment of choice for 
suppressing PTH levels as it can treat underlying 
hypocalcemia as well. 1, 25 dihydroxycholecalciferol 
(calcitriol) is the active form of vitamin D and it not 
only stimulates the phosphate and calcium 
reabsorption from the gut but also plays a vital role in 
bone resorption and bone formation.  However, at the 
same time, reabsorption of calcium and phosphate 
from the bones and gut can pose a risk for 
hypercalcemia and hyperphosphatemia. Vascular 
calcification and coronary artery disease is the leading 
cause of death in the dialysis population. The basic 
reason behind these complications is considered to be 
because of hypercalcemia and hyperphosphatemia.2 So 
in this prospect, a vitamin D analogue that can treat 
secondary hyperparathyroidism with a  limited effect 
on calcium and phosphorus levels can be of attention. 
Alfacalcidol is a commonly used vitamin D analogue 
in Pakistan; however, paricalcitol is not widely 
available. The comparison of their efficacy in tackling 
secondary hyperparathyroidism keeping calcium and 
phosphorus levels within the normal range can be 
helpful in our clinical settings. 
A study of a randomized controlled trial carried out by 
Sprague SM et al compared the efficacy of paricalcitol 
and calcitriol in treating SHPT. The study showed that 
paricalcitol took less time to bring PTH levels within 
the desired range as compared to calcitriol with fewer 
events of hyperphosphatemia.3 Effect on serum 
calcium levels was comparable in both groups.  In 
another study conducted by Brown AJ et al showed 
that paricalcitol is less potent in stimulating intestinal 
calcium and phosphate absorption when compared 
with calcitriol.4 
It has been proposed in a few other studies that 
alfacalcidol has relatively high calcemic and 
phosphatemic action than paricalcitol. Paricalcitol is 
much more expensive than alfacalcidol although 
compliance is not an issue as both are given 
intravenously at the end of the dialysis session. The 
study aimed to look at whether paricalcitol worth it as 
for as suppression of PTH is concerned when 
compared with alfacalcidol. 
 
Materials and Methods 
 
All the patients included in the study were 18 years 
old or more. Patients were recruited from a tertiary 
care hospital and were receiving hemodialysis for at 
least 6 months. Only stable patients, who were having 
no history of malignancy or current pregnancy and 
having a good life expectancy, were included. The 
wash-out period for drugs (if the patient is receiving 
any phosphate binder or calcium supplement) was set 
to be 1 week. Included patients were not receiving any 
kind of vitamin D analogue, their calcium and 
phosphate levels were adequately controlled. i.e.; 
serum corrected calcium less than 10.2 mg/ dL and 
phosphate levels less than 5.5 mg/dL. All the patients 
had iPTH levels of more than 600 pg/mL. 
We divided the patients into two groups. Each group 
comprised of 40 patients, including males and females. 
For sample size calculation proportion of patients 
expected to achieve ≥ 30% decrease in iPTH at the end 
of the treatment, the period was almost 50% in the 
alfacalcidol group and 68% in the paricalcitol group. 
We followed 0.7 controls to recognize a substantial 
peculiarity (P equal to 0.05 on McNemar's test), 80 
individuals had been taken and a randomization list 
was created by a computer. 
The first group of patients with SHPT was treated with 
alfacalcidol (I.V) for about four months. Afterward, 
alfacalcidol was stopped and for the next one week 
patients were off treatment and did not receive any 
vitamin D analogue, calcium supplement, or 
phosphate binders. After completing one week wash-
out period the same group was treated with 
intravenous paricalcitol. The second group of patients 
received paricalcitol (I.V) initially for about four 
months, subsequently had a wash-out period of one 
week, and then treated with alfacalcidol for the next 
four months. Both alfacalcidol and paricalcitol were 
given immediately after completing the HD session in 
I.V form. The initial dose of alfacalcidol was 2μg, 3 
times per week and for paricalcitol, it was 5μg, 3 times 
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per week. However, the dose was adjusted according 
to the monthly iPTH levels, to keep calcium and 
phosphorus within an acceptable range. 
The calcium concentration of dialysate was set to be 
1.5mmol/L and the dialysis concentrate used for each 
patient was HDA49. During pre-dialysis assessment, 
weight, blood pressure, pulse, and other vitals were 
checked for each patient as per routine. 
Blood sample collection protocols were designed. 
Before the start of hemodialysis, all the samples were 
drawn from the arterial bloodlines. Serum calcium, 
phosphate, and iPTH levels were checked every 
month. Based on monthly lab results, required changes 
in the doses of calcium supplement and phosphate 
binders were made. The dose of vitamin D analogues 





We decided on the primary efficacy endpoint, 
secondary outcome, and safety endpoints. The total 
number of patients achieving equal or greater than 
30% reduction in iPTH levels in the last month of 
treatment with either paricalcitol or alfacalcidol was 
labelled as the primary efficacy endpoint. The 
secondary outcome was a change in serum calcium 
and phosphorus levels, and calcium-phosphorus 
product falling out of the desired range. Safety 
endpoints were severe anemia (Hb less than 8), 
thrombocytopenia (Platelets less than 50), 
lymphopenia, severe infection, opportunistic infection, 
persistent hypercalcemia, and hyperphosphatemia or 
liver abnormalities (ALT and AST more than 3 times 
upper limit of normal). 
Diabetes was found in 37% of the patients. 64 % of the 
total patients were male. The mean age of the studied 
patients was 64.5 years (SD 14.5) and the median time 
on dialysis was 37 months (range 32-62 months) at 
randomization. The studied patients were in better 
condition as they had a stable hemoglobin 
10.81mg/dL (SD 0.76) and albumin 40.2 g/L (SD 3.7) 
as compared to other patients. 
 The analysis of the cross-over data for the percentage 
changes in PTH revealed a significant period effect (t = 
-3.946; P). Both vitamin D analogs suppressed 
secondary hyperparathyroidism successfully during 
both treatment periods. We could not detect any 
statistically significant difference in % changes 
between groups, and there was not any statistically 
significant difference in the proportion of patients 
reaching a 30% reduction in PTH. The tables below 
show the confirmation of both periods i.e. periods 1 
and 2.  
 
Table 1: Changes in PTH during each period of 
alfacalcidol and paricalcitol treatment 
Table 1-A: Period 1 













-54.1 ± 5.3 -62.7 ± 3.7 10.7 ± 
(p=0.102) 
Table 1-B: Period 2 














-34.8 ± 6.98 -38 ± 6.71 6.02  ± 8.8 
(p=0.613) 
 
Table 2: Number of patients reaching treatment goal 
during each period of alfacalcidol and paricalcitol 
treatment 





























≥ iPTH  24 (59%) 27 (68%) 0.469 









12 (29%) 16 (41%) 0.466 
 
The analysis of data for the same composite endpoints 
revealed no difference between groups as shown in 
Table 3 below. 
 
Table 3: Number of patients with prolonged 
hypercalcemia or elevated Ca x P product during 
alfacalcidol or paricalcitol treatment in the period 











and Ca x P > 
55 mg2/dL2 














and Ca x P ≥ 
55 mg2/dL2 





15 (37%) 15 (38%) 1.000 
 
The mean PTH during the last four weeks of treatment 
was analyzed with baseline PTH as a covariate and a 
significant baseline PTH x treatment interaction was 
found (P=0.012) which means that treatment response 
depended on baseline PTH in the paricalcitol group, 
whereas alfacalcidol suppressed PTH across all 
baseline PTH values. This interaction was also found 
for numerical changes in PTH (P=0.012), percentage 
changes of PTH (P=0.036) as for the number of 
patients reaching a 30% decrease in PTH (P=0.047). 
Mean PTH during the last four weeks of period 2 were 
analyzed to describe the reproducibility of this 
interaction. The same tendency was found, although 
not statistically significant (P=0.10). However, as there 
were only 80 patients in this analysis, a small number 
of patients studied may be the reason for the lack of 
significance. 
In the present study, the differentiated PTH response 
to paricalcitol across baseline PTH levels may be 
largely due to the pronounced suppression of PTH at 
the low baseline levels. 48% of the paricalcitol treated 
and 29% of the alfacalcidol treated patients reached a 
PTH level of less than 220 pg/ml (P=0.110). The 
observed difference in the effect of alfacalcidol and 
paricalcitol on PTH could be due to a difference in 
calcium levels. This study did not found any 
statistically significant difference between the calcium 
levels in the alfacalcidol group compared to the 
paricalcitol group when groups were separated 




Vitamin D is essential for the optimization of bone 
mineral health. Kidneys produce calcitriol, which is 
the most important metabolite in upholding calcium 
and phosphorus homeostasis. In kidney disease, 
calcitriol levels eventually decrease, resulting in the 
development of secondary hyperparathyroidism 
(SHPT).5 
This randomized control crossover study was 
designed to observe the clinical effects of two vitamin 
D analogs and compare their efficacy in terms of 
treating secondary hyperparathyroidism in the 
dialysis population. Paricalcitol is a relatively new 
drug and still, it is not widely available in the market. 
We compared paricalcitol with conventionally used 
alfacalcidol to compare their effectiveness and side 
effects profile. A similar study was carried out by Ditte 
Hansen et al in 2009 which showed comparable results 
for both paricalcitol and alfacalcidol.6 However, this 
comparison has never been performed in Pakistan 
before. 
Due to differences between the individuals, the end of 
the cross over a design was stochastic variation. 
Deciding the duration of the treatment was a challenge 
because considering an extensive study period carries 
the risk of a large number of patients dropping out 
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sooner than the study finishes. A study carried out in 
Denmark showed a mortality rate of 21.7% in the 
Danish dialysis population.7 So we considered a study 
period of 8 months and included only stable patients 
with good life expectancy. A short study period would 
have been more liable to get biased results.  
We decided one a week washout period for both 
alfacalcidol and paricalcitol groups as keeping patients 
of secondary hyperparathyroidism without any 
vitamin D analog for a longer period of time can pose 
a risk for developing the serious bone mineral disease 
(BMD). A smaller wash-out period may reflect the 
carry-forward effect of drugs from one period to 
another. The half-life mentioned in literature for I.V 
alfacalcidol is 36 hours and 14-30 hours for I.V 
paricalcitol. 
Secondary hyperparathyroidism (SHPT), a common 
complication in the dialysis population, is 
conventionally treated with vitamin D analogs. Several 
studies have been carried out in Europe to compare 
the efficacy of paricalcitol and alfacalcidol. A similar 
study was carried out by Xinghua Geng et al in China 
where the researcher compared paricalcitol with other 
Vitamin D receptor analogs and found that paricalcitol 
is better than others in controlling iPTH levels. He also 
found that paricalcitol has mortality benefits 
compared to other vitamin D analogs.8 
A randomized multicenter study was conducted by 
Daniel W Coyne et al in the USA recently which 
showed that both calcitriol and paricalcitol achieved 
an effective reduction in parathyroid hormone levels 
however paricalcitol suppressed iPTH sooner than 
calcitriol with less incidence of hypercalcemia.9 This 
study was carried out in CKD stage 3-4 patients and 
not in the dialysis population. 
Paricalcitol is a relatively new drug in Pakistan 
however in the USA, it was launched in 1998. It is 
generally considered an effective treatment for SHPT, 
especially in non-compliant patients. 
Hyperphosphatemia and hypercalcemia are common 
side effects that need to be tackled effectively. In 
March 2019, Yang Liu et al published a meta-analysis 
of the safety and efficacy of paricalcitol in dialysis 
patients.10 After reviewing 13 studies, he proposed 
that Paricalcitol has mortality benefits over other 
vitamin D analogs however its effectivity in reducing 
PTH levels was comparable to others. However, two 
similar studies carried out in renal disease patients by 
Yifeng Xie et al and Panpan Cai et al could not provide 
conclusive evidence about the virtual efficacy of 
paricalcitol over other analogs.11,12 
In our study, all the dialysis parameters were kept 
constant and almost identical for all the patients except 
dialyzer size and a dose of Tinzaparin (used as an 
anticoagulant). The selected dialysis patients were in 
better condition than the general hemodialysis 
population, as they had higher hemoglobin 
10.81mg/dl (SD 0.76) vs. 10.19 mg/dl (SD 2.27) and 
albumin 40.2 g/l (SD 3.7) vs. 38.8 g/l (SD 4.8). 
Vitamin D analogs are frequently associated with 
hypercalcemia and hyperphosphatemia but that can be 
controlled with phosphate binders and adjusting the 
dose of vitamin D analog. The doses were adjusted by 
a consultant nephrologist on monthly basis after 
retrieving lab results. Tackling hypercalcemia is 
important as it can lead to vascular calcification and 
increased cardiovascular incidents which can result in 
significant morbidity and mortality.  
In the past 20 years, there have been a few paradigm 
shifts as far as the management of secondary 
hyperparathyroidism is concerned. Nephrologists 
have been using different forms of active vitamin D, 
paricalcitol, and cinacalcet in the near past preferring 
one over the other depending upon clinical scenario 
and local protocols. However, there is a need to avoid 
excessive use of vitamin D analogs and avoid 




The study concludes that there is no difference in the 
ability of alfacalcidol (I.V) and paricalcitol (I.V) to 
suppress secondary hyperparathyroidism while 
keeping phosphate and ionized calcium inside the 
desired range. Based on this study although carried 
out in a small number of patients, we suggest that 
intravenous alfacalcidol is equally effective in treating 
SHPT and due to the high price of paricalcitol, the 
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